Table 2.
Publication year
|
Cell source
|
Induction protocol
|
Material(s) applied
|
Dose/concentration
|
Neurocyte type
|
Culture duration
|
Results
|
Ref.
|
2022 | Human | DMEM + 20% (FBS + P/S + AA + bFGF) | Dental pulp cell sheets | 3200 cells/cm2 | SH-SY5Y neuroblastoma cells | 3 d | Dental pulp cell sheets provided neurotrophic support by expressing NTF; the amount of neurotrophic factors produced by dental pulp cell sheets was sufficient to induce nerve regeneration in vitro and promote nerve repair in vivo; dental pulp cell sheets improved axon guidance and reduced axon branching | [113] |
2020 | Rat | α-MEM + 10% (FBS + P/S + NEAA) | DPSCs-CM | - | TGNCs from rats | 3 wk | DPSCs-CM was found to contain significant levels of nerve growth factor, brain-derived neurotrophic factor, neurotrophic factor-3, and glial cell line-derived neurotrophic factor; DPSCs-CM increased the survival rate of primary trigeminal ganglion neurons and promoted the growth of neurites | [130] |
2020 | Rat | α-MEM + 10% (FBS + P/S + NEAA) | DPSCs-CM | 50% DPSCs-CM | PC12 cells | 8 d | DPSCs-CM was found to contain neurotrophic factors, brain-derived neurotrophic factor, and glial cell line-derived neurotrophic factor, which increased the viability and differentiation of PC12 cells and played an important role in axonal growth and survival, proving that DPSCs-CM treatment is a potential cell-free therapy for peripheral nerve repair and has a stronger effect on PC12 cells than DPSCs | [115] |
AA: Ascorbic acid; bFGF: Basic fibroblast growth factor; DPSCs-CM: DPSCs-conditioned medium; DMEM: Dulbecco’s modified Eagle medium; FBS: Fetal bovine serum; NTF: Neurotrophic factor; NEAA: Nonessential amino acids; P/S: Penicillin and streptomycin; TGNC: Trigeminal ganglion neuronal cells.